A detailed history of Voya Investment Management LLC transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Voya Investment Management LLC holds 25,080 shares of AVXL stock, worth $201,392. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,080
Previous 25,010 0.28%
Holding current value
$201,392
Previous $105,000 35.24%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.11 - $7.04 $287 - $492
70 Added 0.28%
25,080 $142,000
Q2 2024

Aug 14, 2024

BUY
$3.39 - $5.02 $1,013 - $1,500
299 Added 1.21%
25,010 $105,000
Q1 2024

May 15, 2024

SELL
$4.55 - $6.75 $17,581 - $26,082
-3,864 Reduced 13.52%
24,711 $125,000
Q4 2023

Feb 14, 2024

BUY
$5.04 - $9.95 $3,240 - $6,397
643 Added 2.3%
28,575 $266,000
Q2 2023

Aug 14, 2023

BUY
$7.66 - $9.5 $11,865 - $14,715
1,549 Added 5.87%
27,932 $227,000
Q1 2022

May 16, 2022

BUY
$9.74 - $17.69 $12,662 - $22,997
1,300 Added 5.18%
26,383 $325,000
Q4 2021

Feb 14, 2022

BUY
$16.88 - $23.31 $10,836 - $14,965
642 Added 2.63%
25,083 $435,000
Q2 2021

Aug 16, 2021

SELL
$10.16 - $28.86 $10,322 - $29,321
-1,016 Reduced 3.99%
24,441 $559,000
Q1 2021

May 17, 2021

BUY
$5.17 - $16.13 $6,059 - $18,904
1,172 Added 4.83%
25,457 $381,000
Q4 2020

Feb 16, 2021

BUY
$4.01 - $7.58 $22,921 - $43,327
5,716 Added 30.78%
24,285 $131,000
Q2 2020

Aug 14, 2020

SELL
$2.62 - $5.2 $19,896 - $39,488
-7,594 Reduced 29.03%
18,569 $91,000
Q4 2019

Feb 14, 2020

BUY
$2.31 - $3.14 $17,622 - $23,955
7,629 Added 41.16%
26,163 $68,000
Q2 2019

Aug 14, 2019

BUY
$2.75 - $3.7 $50,968 - $68,575
18,534 New
18,534 $62,000
Q2 2018

Aug 14, 2018

SELL
$2.08 - $4.26 $37,897 - $77,617
-18,220 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$3.42 - $4.87 $62,312 - $88,731
18,220
18,220 $75,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $626M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.